Targeted therapies in hepatocellular carcinoma

Current Medicinal Chemistry

Volumn 21, Issue 8, 2014, Pages 966-974

  Bronte, F ^a   Bronte, G ^b   Cusenza, S ^b   Fiorentino, E ^a   Rolfo, C ^c   Cicero, G ^b   Bronte, E ^b   Di Marco, V ^a   Firenze, A ^a   Angarano, G ^d   Fontana, T ^e   Russo, A ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Section of Surgical Oncology   (Italy)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF BARI   (Italy)

^e Hospital of Bisceglie   (Italy)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Liver disease; Targeted therapies

Indexed keywords

BETA CATENIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; SONIC HEDGEHOG PROTEIN; SORAFENIB; WNT PROTEIN;

AKT MEDIATED PATHWAY; ARTICLE; BETA CATENIN MEDIATED PATHWAY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; HEDGEHOG MEDIATED PATHWAY; HUMAN; LIVER CELL CARCINOMA; MAP KINASE MEDIATED PATHWAY; MONOTHERAPY; MTOR MEDIATED PATHWAY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PI3K MEDIATED PATHWAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; WNT SIGNALING PATHWAY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84896342954     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990234     Document Type: Article

References (75)

1. International Agency for Research on Cancer, World Health Organization, The Globocan Project:. http://globocan.iarc.fr
2. Cabibbo, G.; Maida, M.; Genco, C.; Antonucci, M.; Camma, C. Causes of and prevention strategies for hepatocellular carcinoma. Semin. Oncol., 2012, 39(4), 374-383.
3. Plentz, R.R.; Park, Y.N.; Lechel, A.; Kim, H.; Nellessen, F.; Langkopf, B.H.; Wilkens, L.; Destro, A.; Fiamengo, B.; Manns, M.P.; Roncalli, M.; Rudolph, K.L. Telomere shortening and inactivation of cell cycle checkpoints characterize human hepatocarcinogenesis. Hepatology, 2007, 45(4), 968-976.
4. Farazi, P.A.; DePinho, R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer, 2006, 6(9), 674-687.
5. European Association for the Study of the, L.; European Organisation For, R.; Treatment Of, C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol., 2012, 56(4), 908-943.
6. Llovet, J.M.; Bru, C.; Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis., 1999, 19(3), 329-338.
7. Llovet, J.M.; Fuster, J.; Bruix, J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology, 1999, 30(6), 1434-1440.
8. Torzilli, G.; Donadon, M.; Marconi, M.; Palmisano, A.; Del Fabbro, D.; Spinelli, A.; Botea, F.; Montorsi, M. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch. Surg., 2008, 143(11), 1082-1090.
9. Georgiades, C.S.; Hong, K.; D'Angelo, M.; Geschwind, J.F. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J. Vasc. Interv. Radiol., 2005, 16(12), 1653-1659.
10. Heckman, J.T.; Devera, M.B.; Marsh, J.W.; Fontes, P.; Amesur, N.B.; Holloway, S.E.; Nalesnik, M.; Geller, D.A.; Steel, J.L.; Gamblin, T.C. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann. Surg. Oncol., 2008, 15(11), 3169-3177.
11. Dahmani, R.; Just, P.A.; Perret, C. The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol., 2011, 35(11), 709-713.
12. Schmitt-Graeff, A.; Ertelt-Heitzmann, V.; Allgaier, H.P.; Olschewski, M.; Nitschke, R.; Haxelmans, S.; Koelble, K.; Behrens, J.; Blum, H.E. Coordinated expression of cyclin D1 and LEF-1/TCF transcription factor is restricted to a subset of hepatocellular carcinoma. Liver. Int., 2005, 25(4), 839-847.
13. Katoh, H.; Shibata, T.; Kokubu, A.; Ojima, H.; Kosuge, T.; Kanai, Y.; Hirohashi, S. Genetic inactivation of the APC gene contributes to the malignant progression of sporadic hepatocellular carcinoma: a case report. Genes. Chromosomes Cancer, 2006, 45(11), 1050-1057.
14. Liu, J.; Ding, X.; Tang, J.; Cao, Y.; Hu, P.; Zhou, F.; Shan, X.; Cai, X.; Chen, Q.; Ling, N.; Zhang, B.; Bi, Y.; Chen, K.; Ren, H.; Huang, A.; He, T.C.; Tang, N. Enhancement of canonical Wnt/β- catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS One, 2011, 6(11), e27496.
15. Taniguchi, K.; Roberts, L.R.; Aderca, I.N.; Dong, X.; Qian, C.; Murphy, L.M.; Nagorney, D.M.; Burgart, L.J.; Roche, P.C.; Smith, D.I.; Ross, J.A.; Liu, W. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene, 2002, 21(31), 4863-4871.
16. Omenetti, A.; Choi, S.; Michelotti, G.; Diehl, A.M. Hedgehog signaling in the liver. J. Hepatol., 2011, 54(2), 366-373.
17. Blotta, S.; Jakubikova, J.; Calimeri, T.; Roccaro, A.M.; Amodio, N.; Azab, A.K.; Foresta, U.; Mitsiades, C.S.; Rossi, M.; Todoerti, K.; Molica, S.; Morabito, F.; Neri, A.; Tagliaferri, P.; Tassone, P.; Anderson, K.C.; Munshi, N.C. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood, 2012, 120(25), 5002-5013.
18. Calvisi, D.F.; Ladu, S.; Gorden, A.; Farina, M.; Conner, E.A.; Lee, J.S.; Factor, V.M.; Thorgeirsson, S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology, 2006, 130(4), 1117-1128.
19. Huynh, H.; Nguyen, T.T.; Chow, K.H.; Tan, P.H.; Soo, K.C.; Tran, E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol., 2003, 3, 19.
20. Schmidt, C.M.; McKillop, I.H.; Cahill, P.A.; Sitzmann, J.V. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 1997, 236(1), 54-58.
21. Roberts, P.J.; Der, C.J. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene, 2007, 26(22), 3291-3310.
22. Chen, L.; Shi, Y.; Jiang, C.Y.; Wei, L.X.; Wang, Y.L.; Dai, G.H. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. Eur. J. Surg. Oncol., 2011, 37(6), 513-520.
23. Bos, J.L. ras oncogenes in human cancer: a review. Cancer Res., 1989, 49(17), 4682-4689.
24. Wilhelm, S.M.; Adnane, L.; Newell, P.; Villanueva, A.; Llovet, J.M.; Lynch, M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther., 2008, 7(10), 3129-3140.
25. Zhu, A.X.; Stuart, K.; Blaszkowsky, L.S.; Muzikansky, A.; Reitberg, D.P.; Clark, J.W.; Enzinger, P.C.; Bhargava, P.; Meyerhardt, J.A.; Horgan, K.; Fuchs, C.S.; Ryan, D.P. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer, 2007, 110(3), 581-589.
26. Villanueva, A.; Llovet, J.M. Targeted therapies for hepatocellular carcinoma. Gastroenterology, 2011, 140(5), 1410-1426.
27. Tatebe, H.; Shimizu, M.; Shirakami, Y.; Tsurumi, H.; Moriwaki, H. Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin. Cancer Res., 2008, 14(9), 2806-2812.
28. Hopfner, M.; Sutter, A.P.; Huether, A.; Schuppan, D.; Zeitz, M.; Scherubl, H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J. Hepatol., 2004, 41(6), 1008-1016.
29. Thomas, M.B.; Chadha, R.; Glover, K.; Wang, X.; Morris, J.; Brown, T.; Rashid, A.; Dancey, J.; Abbruzzese, J.L. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer, 2007, 110(5), 1059-1067.
30. Bekaii-Saab, T.; Markowitz, J.; Prescott, N.; Sadee, W.; Heerema, N.; Wei, L.; Dai, Z.; Papp, A.; Campbell, A.; Culler, K.; Balint, C.; O'Neil, B.; Lee, R.M.; Zalupski, M.; Dancey, J.; Chen, H.; Grever, M.; Eng, C.; Villalona-Calero, M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin. Cancer Res., 2009, 15(18), 5895-5901.
31. Garcia, J.A.; Roberts, L.R. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. .J Hepatol., 2012, 56(2), 486-487.
32. Tsai, W.C.; Lee, H.S.; Jin, J.S.; Gao, H.W.; Chao, T.K.; Chen, A.; Nieh, S.; Chan, D.C.; Chang, F.N.; Lin, C.K. Association between Osteopontin and EGFR Expression with Clinicopathological Parameters in Hepatocellular Carcinoma. Chin. J. Physiol., 2012, 55(6), 412-420.
33. Zhang, J.K.; Pan, P.L.; Wu, Y.M.; Xiao, J.J.; Peng, J.W. Expression of HER-2/neu oncogene in hepatocellular carcinoma and the clinical implications. Nan Fang Yi Ke Da Xue Xue Bao, 2010, 30(2), 326-328.
34. Kudo, M. mTOR inhibitor for the treatment of hepatocellular carcinoma. Dig. Dis., 2011, 29(3), 310-315.
35. Wang, L.; Wang, W.L.; Zhang, Y.; Guo, S.P.; Zhang, J.; Li, Q.L. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol. Res., 2007, 37(5), 389-396.
36. Semela, D.; Piguet, A.C.; Kolev, M.; Schmitter, K.; Hlushchuk, R.; Djonov, V.; Stoupis, C.; Dufour, J.F. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Hepatol., 2007, 46(5), 840-848.
37. Zhu, A.X.; Abrams, T.A.; Miksad, R.; Blaszkowsky, L.S.; Meyerhardt, J.A.; Zheng, H.; Muzikansky, A.; Clark, J.W.; Kwak, E.L.; Schrag, D.; Jors, K.R.; Fuchs, C.S.; Iafrate, A.J.; Borger, D.R.; Ryan, D.P. hase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer, 2011, 117(22), 5094-5102.
38. Shiah, H.S.; Chen, C.Y.; Dai, C.Y.; Hsiao, C.F.; Lin, Y.J.; Su, W.C.; Chang, J.Y.; Whang-Peng, J.; Lin, P.W.; Huang, J.D.; Chen, L.T. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol. Ther., 2013, 37(1), 62-73.
39. Schnitzbauer, A.A.; Zuelke, C.; Graeb, C.; Rochon, J.; Bilbao, I.; Burra, P.; de Jong, K.P.; Duvoux, C.; Kneteman, N.M.; Adam, R.; Bechstein, W.O.; Becker, T.; Beckebaum, S.; Chazouilleres, O.; Cillo, U.; Colledan, M.; Fandrich, F.; Gugenheim, J.; Hauss, J.P.; Heise, M.; Hidalgo, E.; Jamieson, N.; Konigsrainer, A.; Lamby, P.E.; Lerut, J.P.; Makisalo, H.; Margreiter, R.; Mazzaferro, V.; Mutzbauer, I.; Otto, G.; Pageaux, G.P.; Pinna, A.D.; Pirenne, J.; Rizell, M.; Rossi, G.; Rostaing, L.; Roy, A.; Turrion, V.S.; Schmidt, J.; Troisi, R.I.; van Hoek, B.; Valente, U.; Wolf, P.; Wolters, H.; Mirza, D.F.; Scholz, T.; Steininger, R.; Soderdahl, G.; Strasser, S.I.; Jauch, K.W.; Neuhaus, P.; Schlitt, H.J.; Geissler, E.K. A prospective randomised, open-labeled, trial comparing sirolimuscontaining versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer, 2010, 10, 190.
40. Gedaly, R.; Angulo, P.; Hundley, J.; Daily, M.F.; Chen, C.; Koch, A.; Evers, B.M. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res., 2010, 30(12), 4951-4958.
41. Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J.; Group, S.I.S. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359(4), 378-390.
42. Cheng, A.L.; Kang, Y.K.; Chen, Z.; Tsao, C.J.; Qin, S.; Kim, J.S.; Luo, R.; Feng, J.; Ye, S.; Yang, T.S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W.Y.; Pan, H.; Burock, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol., 2009, 10(1), 25-34.
43. Petrini, I.; Lencioni, M.; Ricasoli, M.; Iannopollo, M.; Orlandini, C.; Oliveri, F.; Bartolozzi, C.; Ricci, S. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol., 2012, 69(3), 773-780.
44. Prete, S.D.; Montella, L.; Caraglia, M.; Maiorino, L.; Cennamo, G.; Montesarchio, V.; Piai, G.; Febbraro, A.; Tarantino, L.; Capasso, E.; Palmieri, G.; Guarrasi, R.; Bianco, M.; Mamone, R.; Savastano, C.; Pisano, A.; Vincenzi, B.; Sabia, A.; D'Agostino, A.; Faiola, V.; Addeo, R. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother. Pharmacol., 2010, 66(5), 837-844.
45. Richly, H.; Schultheis, B.; Adamietz, I.A.; Kupsch, P.; Grubert, M.; Hilger, R.A.; Ludwig, M.; Brendel, E.; Christensen, O.; Strumberg, D. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur. J. Cancer, 2009, 45(4), 579-587.
46. Printz, C. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). Cancer, 2009, 115(20), 4646.
47. Lencioni, R.; Zou, J.; Leberre, M.; Meinhardt, G.; Voliotis, D.; Bruix, J.; Llovet, J.M. Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate- stage hepatocellular carcinoma (SPACE). ASCO Annual Meeting, 2010.
48. Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS). http://www.clinicaltrials.gov/ct2/ show/NCT01217034.
49. Hoffmann, K.; Glimm, H.; Radeleff, B.; Richter, G.; Heining, C.; Schenkel, I.; Zahlten-Hinguranage, A.; Schirrmacher, P.; Schmidt, J.; Buchler, M.W.; Jaeger, D.; von Kalle, C.; Schemmer, P. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN 24081794]. BMC Cancer, 2008, 8, 349.
50. Sansonno, D.; Lauletta, G.; Russi, S.; Conteduca, V.; Sansonno, L.; Dammacco, F. Transarterial chemoembolization plus sorafenib: A sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: A randomized clinical trial. Oncologist, 2012, 17(3), 359-366.
51. Lencioni, R.; Kudo, M.; Ye, S.L.; Bronowicki, J.P.; Chen, X.P.; Dagher, L.; Furuse, J.; Geschwind, J.F.; Ladron de Guevara, L.; Papandreou, C.; Sanyal, A.J.; Takayama, T.; Yoon, S.K.; Nakajima, K.; Cihon, F.; Heldner, S.; Marrero, J.A. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int. J. Clin. Pract., 2012, 66(7), 675-683.
52. P. J. O'Dwyer, B.J. Giantonio., D. E. Levy, J. S. Kauh, D. B. Fitzgerald, A. B. Benson. Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203. J. Clin. Oncol., 2006, 24(18S), 4143. (June 20 Supplement), ASCO Annual Meeting Proceedings (Post-Meeting Edition).
53. Philip, P.A.; Mahoney, M.R.; Allmer, C.; Thomas, J.; Pitot, H.C.; Kim, G.; Donehower, R.C.; Fitch, T.; Picus, J.; Erlichman, C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol., 2005, 23(27), 6657-6663.
54. Kaseb, A.O.; Garrett-Mayer, E.; Morris, J.S.; Xiao, L.; Lin, E.; Onicescu, G.; Hassan, M.M.; Hassabo, H.M.; Iwasaki, M.; Deaton, F.L.; Abbruzzese, J.L.; Thomas, M.B. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology, 2012, 82(2), 67-74.
55. Yau, T.; Wong, H.; Chan, P.; Yao, T.J.; Pang, R.; Cheung, T.T.; Fan, S.T.; Poon, R.T. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest. New Drugs, 2012, 30(6), 2384-2390.
56. Ramanathan, R.K.; Belani, C.P.; Singh, D.A.; Tanaka, M.; Lenz, H.J.; Yen, Y.; Kindler, H.L.; Iqbal, S.; Longmate, J.; Mack, P.C.; Lurje, G.; Gandour-Edwards, R.; Dancey, J.; Gandara, D.R. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother. Pharmacol., 2009, 64(4), 777-783.
57. Siegel, A.B.; Cohen, E.I.; Ocean, A.; Lehrer, D.; Goldenberg, A.; Knox, J.J.; Chen, H.; Clark-Garvey, S.; Weinberg, A.; Mandeli, J.; Christos, P.; Mazumdar, M.; Popa, E.; Brown, R.S., Jr.; Rafii, S.; Schwartz, J.D. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J. Clin. Oncol., 2008, 26(18), 2992-2998.
58. Boige, V.; Malka, D.; Bourredjem, A.; Dromain, C.; Baey, C.; Jacques, N.; Pignon, J.P.; Vimond, N.; Bouvet-Forteau, N.; De Baere, T.; Ducreux, M.; Farace, F. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist, 2012, 17(8), 1063-1072.
59. Hsu, C.H.; Yang, T.S.; Hsu, C.; Toh, H.C.; Epstein, R.J.; Hsiao, L.T.; Chen, P.J.; Lin, Z.Z.; Chao, T.Y.; Cheng, A.L. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br. J. Cancer, 2010, 102(6), 981-986.
60. Sun, W.; Sohal, D.; Haller, D.G.; Mykulowycz, K.; Rosen, M.; Soulen, M.C.; Caparro, M.; Teitelbaum, U.R.; Giantonio, B.; O'Dwyer, P.J.; Shaked, A.; Reddy, R.; Olthoff, K. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer, 2011, 117(14), 3187-3192.
61. Buijs, M.; Reyes, D.K.; Pawlik, T.M.; Blackford, A.L.; Salem, R.; Messersmith, W.A.; Weekes, C.D.; Mulcahy, M.; Kamel, I.R.; Geschwind, J.F. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer, 2013, 119(5), 1042-1049.
62. Choo, S.P.; Chowbay, B.; Ng, Q.S.; Thng, C.H.; Lim, C.; Hartono, S.; Koh, T.S.; Huynh, H.; Poon, D.; Ang, M.K.; Chang, S.; Toh, H.C. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma. Eur. J. Cancer, 2013, 49(5), 999-1008.
63. Park, J.W.; Finn, R.S.; Kim, J.S.; Karwal, M.; Li, R.K.; Ismail, F.; Thomas, M.; Harris, R.; Baudelet, C.; Walters, I.; Raoul, J.L. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res., 2011, 17(7), 1973-1983.
64. JM Llovet, T.D., J-L Raoul, et al. . In 47th International Liver Congress (EASL 2012): Barcelona, 2012.
65. Finn, R.S.; Kang, Y.K.; Mulcahy, M.; Polite, B.N.; Lim, H.Y.; Walters, I.; Baudelet, C.; Manekas, D.; Park, J.W. Phase II, openlabel study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res., 2012, 18(7), 2090-2098.
66. Toh, H.C.; Chen, P.J.; Carr, B.I.; Knox, J.J.; Gill, S.; Ansell, P.; McKeegan, E.M.; Dowell, B.; Pedersen, M.; Qin, Q.; Qian, J.; Scappaticci, F.A.; Ricker, J.L.; Carlson, D.M.; Yong, W.P. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer, 2013, 119(2), 380-387.
67. Zhu, A.X.; Sahani, D.V.; Duda, D.G.; di Tomaso, E.; Ancukiewicz, M.; Catalano, O.A.; Sindhwani, V.; Blaszkowsky, L.S.; Yoon, S.S.; Lahdenranta, J.; Bhargava, P.; Meyerhardt, J.; Clark, J.W.; Kwak, E.L.; Hezel, A.F.; Miksad, R.; Abrams, T.A.; Enzinger, P.C.; Fuchs, C.S.; Ryan, D.P.; Jain, R.K. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol., 2009, 27(18), 3027-3035.
68. Faivre, S.; Raymond, E.; Boucher, E.; Douillard, J.; Lim, H.Y.; Kim, J.S.; Zappa, M.; Lanzalone, S.; Lin, X.; Deprimo, S.; Harmon, C.; Ruiz-Garcia, A.; Lechuga, M.J.; Cheng, A.L. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol., 2009, 10(8), 794-800.
69. Koeberle, D.; Montemurro, M.; Samaras, P.; Majno, P.; Simcock, M.; Limacher, A.; Lerch, S.; Kovacs, K.; Inauen, R.; Hess, V.; Saletti, P.; Borner, M.; Roth, A.; Bodoky, G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist, 2010, 15(3), 285-292.
70. Worns, M.A.; Schuchmann, M.; Duber, C.; Otto, G.; Galle, P.R.; Weinmann, A. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology, 2010, 79(1-2), 85-92.
71. O'Neil, B.H.; Goff, L.W.; Kauh, J.S.; Strosberg, J.R.; Bekaii-Saab, T.S.; Lee, R.M.; Kazi, A.; Moore, D.T.; Learoyd, M.; Lush, R.M.; Sebti, S.M.; Sullivan, D.M. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol., 2011, 29(17), 2350-2356.
72. Alberts, S.R.; Fitch, T.R.; Kim, G.P.; Morlan, B.W.; Dakhil, S.R.; Gross, H.M.; Nair, S. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am. J. Clin. Oncol., 2012, 35(4), 329-333.
73. Rizell, M.; Andersson, M.; Cahlin, C.; Hafstrom, L.; Olausson, M.; Lindner, P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int. J. Clin. Oncol., 2008, 13(1), 66-70.
74. Decaens, T.; Luciani, A.; Itti, E.; Hulin, A.; Roudot-Thoraval, F.; Laurent, A.; Zafrani, E.S.; Mallat, A.; Duvoux, C. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig. Liver Dis., 2012, 44(7), 610-616.
75. Mo, M.H.; Chen, L.; Fu, Y.; Wang, W.; Fu, S.W. Cell-free Circulating miRNA Biomarkers in Cancer. J. Cancer, 2012, 3, 432-448.